Your browser doesn't support javascript.
loading
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays.
Galior, Kornelia D; Ladwig, Paula M; Snyder, Melissa R; Algeciras-Schimnich, Alicia; Bornhorst, Joshua A; Block, Darci R; Baumann, Nikola A; Willrich, Maria Alice V.
Afiliação
  • Galior KD; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. Electronic address: kgalior@emory.edu.
  • Ladwig PM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Snyder MR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Algeciras-Schimnich A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Bornhorst JA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Block DR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Baumann NA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Willrich MAV; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: willrich.mariaalice@mayo.edu.
Clin Biochem ; 121-122: 110685, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37972806
BACKGROUND: Therapeutic monoclonal antibodies (tmabs) have been hypothesized to interfere with immunoassay measurements, although studies investigating this potential new class of interference are lacking. This study evaluated the effects of tmabs used in cancers ipilimumab (Bristol Myers Squibb), nivolumab (Bristol Myers Squibb), pembrolizumab (Merck) and autoimmune disorders adalimumab (AbbVie), infliximab (Janssen) and vedolizumab (Takeda) in common immunoassays used in the clinical laboratory. METHODS: Residual sera from 10 randomly chosen patients were split into two tubes and spiked with same volume (approximately 5 % final volume) of either saline (control) or 6 tmabs (final concentration of 100 µg/mL each). Concentrations from sixteen analytes in 19 different assays were assessed: TSH (Roche and Beckman), free thyroxine (Roche and Siemens), cortisol (Beckman), Cancer Antigens (CA): CA19-9 (Beckman), CA15-3 (Roche), CA125 (Roche), and CA27.29 (Siemens), carcinoembryonic antigen (Beckman), alpha-fetoprotein (Beckman), thyroglobulin (Beckman) and thyroglobulin antibodies (Beckman), thyroid peroxidase antibody (Beckman), beta-human chorionic gonadotropin (Roche and Beckman), total prostate-specific antigen (Roche), parathyroid hormone (Roche) and antinuclear antibodies IgG (Werfen). The tmab spiked residual sera were compared with matched saline spiked sera and percent error was assessed against allowable total error defined from biological variation or CLIA limits. RESULTS: None of the tested immunoassays were affected by the presence of the tmabs, in samples within or outside assay reference intervals. The median % error among all immunoassays ranged between -2.0% (for TSH) to 2.7% (for TPO Ab assay). CONCLUSION: These findings demonstrate no detectable tmab interference for the assessed immunoassays using spiked preparations of the tmabs in residual human sera. The findings are limited to the tmabs and immunoassays studied here.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Monoclonais Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Anticorpos Monoclonais Idioma: En Ano de publicação: 2023 Tipo de documento: Article